首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence
【2h】

Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence

机译:全身性硬化症血清明显损害多步骤淋巴管生成过程:体外证据。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In systemic sclerosis (SSc), the possible involvement of lymphatic microcirculation and lymphangiogenesis has traditionally been overshadowed by the greater emphasis placed on dysfunctional blood vascular system and angiogenesis. In the present in vitro study, we explore for the first time whether the SSc microenvironment may interfere with lymphangiogenesis, a complex, multi-step process in which lymphatic microvascular endothelial cells (LMVECs) sprout, migrate, and proliferate to generate new lymphatic capillaries. Normal human adult dermal LMVECs from three donors were treated with serum from SSc patients ( = 8), serum from healthy individuals ( = 8), or recombinant human vascular endothelial growth factor (VEGF)-C as a positive control for lymphangiogenesis. Cell proliferation, Boyden chamber Matrigel chemoinvasion, wound healing capacity, and lymphatic capillary morphogenesis on Geltrex were assayed. VEGF-C serum levels were measured by enzyme-linked immunosorbent assay. Gene and protein expression levels of the lymphangiogenic orchestrators VEGF receptor-3 (VEGFR-3)/Flt-4 and neuropilin-2 (NRP-2) were determined by real-time PCR and Western blotting, respectively. Conditioning with SSc serum significantly inhibited LMVEC proliferation, Matrigel invasion, and wound healing capacity with respect to healthy serum. The ability of LMVECs to form lymphatic tubes on Geltrex was also severely compromised in the presence of SSc serum. VEGF-C levels were comparable in SSc and healthy sera. Treatment with SSc serum resulted in a significant downregulation of both VEGFR-3/Flt-4 and NRP-2 mRNA and protein levels. In SSc, the pathologic environment severely hampers every lymphangiogenesis step, likely through the reduction of pro-lymphangiogenic VEGFR-3/NRP-2 co-receptor signaling. The impairment of the lymphangiogenic process opens a new scenario underlying SSc vascular pathophysiology, which is worth investigating further.
机译:在系统性硬化症(SSc)中,淋巴微循环和淋巴管生成的可能参与传统上已被功能性血管系统和血管生成的更多重视所掩盖。在目前的体外研究中,我们首次探索SSc微环境是否会干扰淋巴管生成,这是一个复杂的,多步骤的过程,其中淋巴微血管内皮细胞(LMVEC)萌发,迁移并增殖以生成新的淋巴毛细血管。用来自SSc患者的血清(= 8),健康个体的血清(= 8)或重组人血管内皮生长因子(VEGF)-C处理来自三个供体的正常人成人真皮LMVEC作为淋巴管生成的阳性对照。检测细胞的增殖,Boyden室基质胶的化学浸润,伤口愈合能力以及Geltrex上的淋巴管形态。通过酶联免疫吸附测定法测量VEGF-C血清水平。分别通过实时PCR和Western印迹法测定淋巴管生成协调器VEGF受体3(VEGFR-3)/ Flt-4和神经菌毛素2(NRP-2)的基因和蛋白质表达水平。相对于健康血清,用SSc血清进行调理可显着抑制LMVEC增殖,基质胶侵袭和伤口愈合能力。在存在SSc血清的情况下,LMVEC在Geltrex上形成淋巴管的能力也受到严重损害。 SSc和健康血清中的VEGF-C水平相当。用SSc血清处理导致VEGFR-3 / Flt-4和NRP-2 mRNA和蛋白质水平显着下调。在SSc中,病理环境可能严重阻碍了每个淋巴管生成步骤,很可能是通过减少促淋巴管生成的VEGFR-3 / NRP-2共受体信号传导来实现的。淋巴管生成过程的损伤为SSc血管病理生理学开启了新的局面,值得进一步研究。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号